Brief Article
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 21, 2014; 20(3): 786-794
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.786
Table 2 Incidence of adverse events in 44 patients with cirrhosis and hepatocellular carcinoma undergoing treatment with sorafenib n (%)
Adverse eventsStatistics
Fatigue29 (65.9)
Grade 111 (25.0)
Grade 211 (25.0)
Grade 37 (15.9)
Bleeding7 (15.9)
Grade 13 (6.8)
Grade 21 (2.3)
Grade 33 (6.8)
Hand-foot syndrome14 (31.8)
Grade 17 (15.9)
Grade 27 (15.9)
Grade 30 (0.0)
Diarrhea15 (34.1)
Grade 16 (13.6)
Grade 28 (18.2)
Grade 31 (2.3)
Hepatic grade 31AEs8 (18.2)
Other AEs220 (45.5)